EUVIMEDSkopri EUVIMED
Crossref

Icaritin exhibits potential drug–drug interactions through the inhibition of human UDP‐glucuronosyltransferase in vitro

Yi Rong, Nanxi Li, Xuan Qiao, Lei Yang, Peng Han, Zhiyun Meng, Hui Gan, Zhuona Wu, Xiaoxia Zhu, Yunbo Sun, Shuchen Liu, Guifang Dou and 1 more

Biopharmaceutics & Drug Disposition · 2024

DOI: 10.1002/bdd.2397 ↗

At a glance

Journal article in Biopharmaceutics & Drug Disposition, 2024. Written by Yi Rong and 12 co-authors. Institution: Office of Pharmacotoxicology, Center for Drug Evaluation, NMPA, Beijing, China. Major MEDLINE topics: Glucuronosyltransferase, Flavonoids, Microsomes, Liver, Drug Interactions. Cited 2 times so far (Crossref); 34 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Icaritin is a prenylflavonoid derivative of the genus Epimedium (Berberidaceae) and has a variety of pharmacological actions. Icaritin is approved by the National Medical Products Administration as an anticancer drug that exhibits efficacy and safety advantages in patients with hepatocellular carcinoma cells. This study aimed to evaluate the inhibitory effects of icaritin on UDP‐glucuronosyltransferase (UGT) isoforms. 4‐Methylumbelliferone (4‐MU) was employed as a probe drug for all the tested UGT isoforms using in vitro human liver microsomes (HLM). The inhibition potentials of UGT1A1 and 1A9 in HLM were further tested by employing 17β‐estradiol (E2) and propofol (PRO) as probe substrates, respectively. The results showed that icaritin inhibits UGT1A1, 1A3, 1A4, 1A7, 1A8, 1A10, 2B7, and 2B15. Furthermore, icaritin exhibited a mixed inhibition of UGT1A1, 1A3, and 1A9, and the inhibition kinetic parameters (K i ) were calculated to be 3.538, 2.117, and 0.306 (μM), respectively. The inhibition of human liver microsomal UGT1A1 and 1A9 both followed mixed mechanism, with K i values of 2.694 and 1.431 (μM). This study provides supporting information for understanding the drug–drug interaction (DDI) potential of the flavonoid icaritin and other UGT‐metabolized drugs in clinical settings. In addition, the findings provide safety evidence for DDI when liver cancer patients receive a combination therapy including icaritin.

Subjects

MeSH terms (MEDLINE)

GlucuronosyltransferaseFlavonoidsMicrosomes, LiverDrug InteractionsHumansEstradiolHymecromonePropofolEnzyme Inhibitors

Author keywords

UDP‐glucuronosyltransferase (UGT)drug–drug interaction (DDI)icaritin

Substances

GlucuronosyltransferaseicaritinFlavonoidsEstradiolHymecromonePropofolEnzyme Inhibitors

Authors and institutions

  • Office of Pharmacotoxicology, Center for Drug Evaluation, NMPA, Beijing, China.
  • Beijing Institute of Radiation Medicine, Beijing, China.

Cite

APA

Rong, Y., Li, N., Qiao, X., Yang, L., Han, P., Meng, Z., Gan, H., Wu, Z., Zhu, X., Sun, Y., Liu, S., Dou, G., & Gu, R. (2024). Icaritin exhibits potential drug–drug interactions through the inhibition of human UDP‐glucuronosyltransferase in vitro. Biopharmaceutics & Drug Disposition. https://doi.org/10.1002/bdd.2397

Vancouver

Rong Y, Li N, Qiao X, Yang L, Han P, Meng Z, et al. Icaritin exhibits potential drug–drug interactions through the inhibition of human UDP‐glucuronosyltransferase in vitro. Biopharmaceutics & Drug Disposition. 2024. doi:10.1002/bdd.2397

BibTeX
@article{Rong2024,
  author = {Rong, Yi and Li, Nanxi and Qiao, Xuan and Yang, Lei and Han, Peng and Meng, Zhiyun and Gan, Hui and Wu, Zhuona and Zhu, Xiaoxia and Sun, Yunbo and Liu, Shuchen and Dou, Guifang and Gu, Ruolan},
  title = {Icaritin exhibits potential drug–drug interactions through the inhibition of human UDP‐glucuronosyltransferase in vitro},
  journal = {Biopharmaceutics & Drug Disposition},
  year = {2024},
  doi = {10.1002/bdd.2397}
}
Start for free →